In the current study, we set out to investigate the hypothesis that the deletion of DLEU1 in BL may affect the expression of DLEU1 network genes and alter signal transduction pathways leading to the inhibition of programmed cell death and in part be responsible for the mechanism of resistance to chemoimmunotherapy in patients with BL with a 13q14.3 deletion. This evidence concerns the gene DLEU1 and Burkitt lymphoma.